March 16, 2026 · BMJ (Clinical research ed.) · DOI: 10.1136/bmj-2025-087259

Pyrotinib or placebo in combination with trastuzumab and docetaxel for HER2 positive metastatic breast cancer: long term survival results from randomised phase 3 PHILA trial

Listen to this summary

The authors of the phase 3 PHILA trial aimed to evaluate the efficacy and safety of pyrotinib, in combination with trastuzumab and docetaxel, compared to placebo in patients with untreated HER2 positive metastatic breast cancer. The updated results demonstrated that the pyrotinib regimen significantly improved both progression-free survival and overall survival, while maintaining a consistent safety profile. These findings support the use of this dual anti-HER2 treatment strategy as an effective initial therapy for this patient population.

Fei Ma, Min Yan, Wei Li, Quchang Ouyang, Zhongsheng Tong, Yuee Teng, Yongsheng Wang, Shusen Wang, Cuizhi Geng, Ting Luo, Jincai Zhong, Qingyuan Zhang, Qiang Liu, Xiaohua Zeng, Tao Sun, Qinguo Mo, Shoubing Zhou, Peidong Li, Jing Cheng, Xiaojia Wang, Jianyun Nie, Jin Yang, Xinhong Wu, Xinshuai Wang, Huiping Li, Guangyu Yao, Yang Fan, Jiaman Lin, Xiaoyu Zhu, Binghe Xu

This is one of 33,000+ journals available on OSLR. Try it free for 14 days.

Free 14-day trial. 33,000+ journals. Cancel anytime.

14-day free trial. No commitment.

"Oslr has become part of my weekly routine on my day off. The clinical relevance of the summaries is outstanding — I'd rate it 9/10. Being able to consume research hands-free is a huge advantage for busy physicians."

Dr. Jennifer Thompson

Dr. Jennifer Thompson

Portland, OR

Stay current without falling behind

33,000+ journals. 3-minute audio summaries. Free for 14 days.

Download on the App StoreGet it on Google Play